CING Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cingulate Inc (CING) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. The technical indicators are neutral to bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to justify immediate investment. Holding off for further developments, such as FDA approval for their drug application or improved financial metrics, would be prudent.
The MACD is negatively expanding, indicating bearish momentum. RSI is at 31.901, which is neutral but close to oversold territory. Moving averages are converging, showing no clear trend. Key support is at 6.489, and the stock is trading near this level, with resistance levels at 10.883 and 12.239.
The company's new drug application for CTx-1301 in ADHD is awaiting an FDA decision with a May 31 action date, which could act as a positive catalyst if approved.
Weak financial performance with negative net income (-$6.27M) and declining EPS (-50.79% YoY). No recent news or significant insider/hedge fund trading trends. The stock has a low probability of significant short-term gains based on historical patterns.
In Q4 2025, revenue remained at $0 with no growth. Net income improved slightly (-0.67% YoY) but remains negative. EPS dropped significantly (-50.79% YoY), and gross margin is at 0%. Overall, financials are weak and do not support a strong investment case.
Roth Capital recently lowered the price target from $16 to $14 but maintained a Buy rating. The firm updated its model to reflect Q4 results, which were weak. The Buy rating seems contingent on the FDA decision for CTx-1301.
